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Background: Approximately 20% of all colorectal cancers are hypothesized to arise from
the “serrated pathway” characterized by mutation in BRAF, high-level CpG Island Methy-
lator Phenotype, and microsatellite instability/mismatch repair (MMR)-deficiency. MMR-
deficient cancers show frequent losses of Cdx2, a homeodomain transcription factor. Here,
we determine the predictive value of Cdx2 expression for MMR-deficiency and investigate
changes in expression between primary cancers and matched lymph node metastases.
Methods: Immunohistochemistry for Cdx2, Mlh1, Msh2, Msh6, and Pms2 was performed
on whole tissue sections from 201 patients with primary colorectal cancer and 59 cases
of matched lymph node metastases. Receiver operating characteristic curve analysis and
Area under the Curve (AUC) were investigated; association of Cdx2 with clinicopathological
features and patient survival was carried out.
Results: Loss of Cdx2 expression was associated with higher tumor grade (p=0.0002),
advanced pT (p=0.0166), and perineural invasion (p=0.0228). Cdx2 loss was an unfa-
vorable prognostic factor in univariate (p=0.0145) and multivariate [p=0.0427; HR (95%
CI): 0.58 (0.34–0.98)] analysis.The accuracy (AUC) for discriminating MMR-proficient and –
deficient cancers was 87% [OR (95% CI): 0.96 (0.95–0.98); p<0.0001]. Specificity and
negative predictive value for MMR-deficiency was 99.1 and 96.3%. One hundred and
seventy-four patients had MMR-proficient cancers, of which 60 (34.5%) showed Cdx2
loss. Cdx2 loss in metastases was related to MMR-deficiency (p<0.0001). There was no
difference in expression between primary tumors and matched metastases.
Conclusion: Loss of Cdx2 is a sensitive and specific predictor of MMR-deficiency, but is
not limited to these tumors, suggesting that events “upstream” of the development of
microsatellite instability may impact Cdx2 expression.
Keywords: colorectal cancer, Cdx2, mismatch repair, microsatellite instability
INTRODUCTION
Colorectal cancer is a heterogeneous disease at the clinical,
histopathological, and molecular level (1). Several molecular clas-
sifications of colorectal cancer based on features such as chromoso-
mal instability, point mutations (APC, KRAS, BRAF), microsatel-
lite instability (MSI), and CpG island methylation have been
proposed (2–4). It is now generally accepted that approximately
20% of all colorectal cancers arise from serrated adenomas that
have undergone a series of genetic changes (5). In the earliest
phase of this “serrated pathway” it is hypothesized that muta-
tional activation of BRAF leads to an initial burst in proliferation
within the normal colonic epithelium followed by p16-induced cell
senescence (oncogene-activated senescence) (6, 7). Escape from
senescence would be achieved by methylation of p16INK4A, loss
of p53 function, or silencing of insulin-like growth factor binding
protein 7 (IGFBP7). Responsible for this silencing is the CpG
Island Methylator Phenotype (CIMP), a state of aberrant methy-
lation of promoter region CpG islands associated with transcrip-
tional inactivation of tumor suppressor genes (8). These changes
lead to the development of sessile serrated adenomas (SSA) that
may eventually progress to colorectal cancers (4).
Importantly, among the relevant tumor suppressor genes fre-
quently silenced by CIMP is MLH1, a critical gene involved in
DNA mismatch repair (9, 10). When hypermethylated, MLH1 con-
tributes to the development of MSI,a feature observed in 15% of all
cases. Defects in the DNA mismatch repair system can be observed
by immunohistochemistry for microsatellite instability/mismatch
repair (MMR) proteins, such as Mlh1, Msh2, Msh6, and Pms2
(11, 12) with negativity in any one of these proteins a sign of
MMR-deficiency.
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Interestingly, some studies have observed that MMR-deficient
colorectal cancers show a frequent loss of Cdx2, a tumor suppres-
sor gene and homeodomain transcription factor that functions to
regulate intestinal epithelial cell differentiation (13–15). Reduced
Cdx2 expression has additionally been associated with increased
migration and invasion of cancer cells and may play a role in
the epithelial mesenchymal transition (EMT) by disrupting WNT
pathway signaling (16–21).
The aim of this study is to determine the predictive value of
Cdx2 expression for MMR-deficiency, the association with clini-
copathological features and patient survival as well as to investigate
changes in Cdx2 expression between primary cancers and matched
lymph node metastases.
PATIENTS AND METHODS
PATIENTS
The patient cohort consisted of 201 non-consecutive patients
treated at the Visceral and Transplantation Surgery depart-
ment the Insel Hospital in Bern, Switzerland between 2002
and 2011. Gender and age information was available for all
patients. Histopathology was systematically re-reviewed. TNM
staging was performed in accordance with the seventh edition
of the AJCC/UICC staging manual. Clinical metastasis staging
(cM) information was available for 190 patients. Lymphatic,
venous, and perineural invasion could be reviewed on a major-
ity of cases. Information on adjuvant therapy was available for
197 patients and survival time for 93 patients. No patients
received neoadjuvant therapy. Median overall survival time was
54.6 months.
SPECIMEN CHARACTERISTICS
Formalin fixed (10% neutral buffered formalin) paraffin-
embedded tumor blocks were retrieved from the Institute of
Pathology, University of Bern, Switzerland. One representa-
tive tumor block of primary cancer and lymph node metas-
tases was identified for immunohistochemistry. Ethical con-
sent was obtained from the local ethics commission for both
groups.
IMMUNOHISTOCHEMISTRY
Immunohistochemistry was carried out on whole tissue sections,
cut at 4µm, for all primary colorectal cancers and lymph nodes
(Cdx2, Mlh1, Msh2, Msh6, and Pms2). Negative controls were
tested with omission of the primary antibodies. An automated
Bond III instrument was used along with the following anti-
bodies and protocols: Cdx2, Leica-Novocastra, NCL-Cdx2, 1:200,
Tris 95°, 30 min; MLH1, Leica-Novocastra, NCL-MLH1, 1:200,
Tris 95°, 30 min; MSH2, Leica-Novocastra, NCL-MSH2, 1:200, Tris
95°, 30 min; MSH6, Leica-Novocastra, MSH6-L-CE, 1:1600, Tris
95°, 30 min; PMS2, Leica-Novocastra NCL-L-PMS2, 1:75, Tris 95°,
30 min. For Cdx2 expression, the percentage of positive tumor
cells was estimated. For MMR proteins, any tumor cell expres-
sion was defined as positivity for that marker. MMR-deficiency
was assigned to cases showing loss of any of the four proteins.
Since information on family history was unavailable, no attempt
was made to further subdivide patients into Lynch syndrome or
sporadic MSI.
STATISTICS
The association between Cdx2 expression as continuous variable
and MMR status (proficient versus deficient) was investigated
using simple logistic regression analysis. Odds ratio (OR) and
95% confidence intervals (CI) were used to determine effect size.
The area under the receiver operating characteristic (ROC) curve
(AUC) was used to determine the discriminatory ability of Cdx2
expression for MMR-deficiency,with values closer to 1.0 indicating
a better discrimination. Cutoffs for Cdx2 focal and diffuse expres-
sion were also assessed by ROC curve analysis, by selecting the
point on the curve giving the highest sensitivity and specificity for
MMR-deficiency. For the association with age, a Wilcoxon’s Test
was used and to test the difference in expression between tumor
and lymph node, a Wilcoxon’s Signed Rank Test for matched pairs.
Univariate survival analysis was performed using the log-rank and
Wilcoxon’s tests. Multivariable survival analysis was carried out
using Cox regression analysis, with “loss” of Cdx2 used as a base-
line. Hazard ratios and 95% CI were used to determine the effect
of Cdx2 expression on overall survival. p-Values <0.05 were con-
sidered statistically significant. All analyses were carried out using
SAS V9.2 (The SAS Institute, Cary, NC, USA).
RESULTS
PATIENT CHARACTERISTICS
Patient characteristics are shown in Table 1. Whole tissue sections
from 201 patients were evaluated for Cdx2 expression. Of these,
59 patients had available lymph node metastases that underwent
Cdx2 staining as well. Representative photomicrographs are shown
in Figures 1A,B.
ASSOCIATION OF Cdx2 IN TUMOR AND LYMPH NODES WITH
CLINICOPATHOLOGICAL FEATURES
Focal Cdx2 expression was significantly more frequent in colorec-
tal cancers with mucinous histology (p= 0.0053), higher tumor
grade (p= 0.0002), more advanced pT stage (p= 0.0166), with
perineural invasion (p= 0.0228), and in those receiving adju-
vant therapy (p= 0.0058). In addition, there was a significant
and adverse effect of Cdx2 loss on patient survival (p= 0.0145;
Figure 2A). This result was maintained in multivariable analy-
sis with pT and pN classifications [p= 0.0427; HR (95% CI): 0.58
(0.34–0.98)] but not when clinical metastasis staging was included
in the model. Although not statistically significant, possibly due to
a smaller number of patients, loss of Cdx2 seemed to occur more
frequently in tumors with lymphatic invasion (p= 0.0809), and in
patients with metastasis (p= 0.0887).
Table 2 shows the associations between lymph node expression
of Cdx2 and clinicopathological features of the primary cancers.
Indeed, only tumor location was linked to loss of Cdx2 expres-
sion, which occurs more frequently in the right-side of the colon
(p= 0.0088). Of the 59 patients with evaluable lymph nodes, infor-
mation on survival was only available in 26. Loss of Cdx2 in lymph
node metastasis was marginally associated with overall survival
(p= 0.0512).
Evaluating the matched lymph nodes and primary colorectal
cancers, average expression was 66.7% in lymph nodes and 71.0%
in primary tumors. Using a matched pairs analysis, this difference
was not significant (p= 0.5801).
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Table 1 | Patient characteristics (n=201) and association with Cdx2 expression in tumor.
Feature Frequency N (%) Frequency N (%) Frequency N (%) p-Value
Total Focal Cdx2 Diffuse Cdx2
Gender (n=201) Male 125 (62.2) 51 (59.3) 74 (64.4) 0.4655
Female 76 (37.8) 35 (40.7) 41 (35.7)
Age (years) (n=201) Median (range) 72.0 (19–91) 70.9 (19–90) 73 (48–91) 0.0825
Tumor location (n=200) Left 76 (38.0) 28 (32.9) 48 (41.7) 0.3806
Rectum 29 (14.5) 12 (14.1) 17 (14.8)
Right 95 (47.5) 45 (52.9) 50 (43.5)
Histological subtype (n=200) Non-mucinous 162 (81.0) 62 (72.1) 100 (87.7) 0.0053
Mucinous 38 (19.0) 24 (27.9) 14 (12.3)
Tumor grade (n=199) G1–2 140 (70.4) 48 (56.5) 92 (80.7) 0.0002
G3 59 (29.6) 37 (43.5) 22 (19.3)
pT (n=201) pT1–2 47 (23.4) 13 (15.1) 34 (29.6) 0.0166
pT3–4 154 (76.6) 73 (84.9) 81 (70.4)
pN (n=200) pN0 92 (46.0) 32 (37.2) 60 (52.6) 0.0303
pN1–2 108 (54.0) 54 (62.8) 54 (47.4)
Metastasis (n=190) cM0 133 (70.0) 50 (63.3) 83 (74.8) 0.0887
cM1 57 (30.0) 29 (36.7) 28 (25.2)
Perineural invasion (n=111) Absence 97 (87.4) 38 (79.2) 59 (93.7) 0.0228
Presence 14 (12.6) 10 (20.8) 4 (6.4)
Venous invasion (n=132) Absence 59 (44.7) 21 (37.5) 38 (50.0) 0.1534
Presence 73 (55.3) 35 (62.5) 38 (50.0)
Lymphatic invasion (n=128) Absence 32 (25.0) 10 (17.5) 22 (31.0) 0.0809
Presence 96 (75.0) 47 (82.5) 49 (69.0)
Adjuvant therapy (n=197) None 135 (68.5) 48 (57.8) 87 (76.3) 0.0058
Treated 62 (31.5) 35 (42.2) 27 (23.7)
Mismatch repair status (n=201) Proficient 174 (86.6) 60 (69.8) 114 (99.1) <0.0001
Deficient 27 (13.4) 26 (30.2) 1 (0.9)
Overall survival (n=93) Median (95%CI) 54.6 (28–72) 26.4 (10–61) 68.7 (44–101) 0.0145
FIGURE 1 | (A) Diffuse and (B) focal expression of Cdx2 in colorectal cancers.
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FIGURE 2 | (A) Kaplan–Meier survival curve showing effect of Cdx2
expression on overall survival (n=93). (B) ROC curve highlighting the strong
predictive effect and specificity of loss of Cdx2 expression for
MMR-deficiency. (C) Kaplan–Meier survival curve showing effect of Cdx2
expression on overall survival in MMR-proficient colorectal cancer patients
only (n=78). Wilcoxon’s test.
Table 2 | Association of Cdx2 loss in tumor and lymph nodes with clinicopathological features (n=59).
Feature Lymph node metastases (n=59)
Cdx2 focal Diffuse p-Value
Gender (n=59) Male 9 (64.3) 29 (64.4) 1.0
Female 5 (35.7) 16 (35.6)
Age (years) (n=59) Median (range) 71 (19–87) 74 (30–91) 0.1169
Tumor location (n=58) Left 1 (7.1) 20 (45.5) 0.0088
Right 5 (35.7) 4 (9.1)
Rectum 8 (57.1) 20 (45.5)
Histological subtype (n=59) Non-mucinous 10 (71.4) 34 (75.6) 0.7376
Mucinous 4 (28.6) 11 (24.4)
Tumor grade (n=59) G1–2 7 (50.0) 32 (71.1) 0.3156
G3 7 (50.0) 13 (28.9)
pT (n=59) pT1–2 2 (14.3) 4 (8.9) 0.6204
pT3–4 12 (85.7) 41 (91.1)
Metastasis (n=56) cM0 9 (75.0) 23 (52.3) 0.1585
cM1 3 (25.0) 21 (47.7)
Perineural invasion (n=33) Absence 6 (75.0) 20 (80.0) 1.0
Presence 2 (25.0) 5 (20.0)
Venous invasion (n=41) Absence 2 (18.2) 8 (26.7) 0.7004
Presence 9 (81.8) 22 (73.3)
Lymphatic invasion (n=44) Absence 1 (8.3) 1 (3.1) 0.4757
Presence 11 (91.7) 31 (96.9)
Adjuvant therapy (n=59) None 7 (50.0) 23 (51.1) 0.9421
Treated 7 (50.0) 22 (48.9)
Mismatch repair status (n=59) MMR-proficient 7 (50.0) 43 (95.6) <0.0001
MMR-deficient 7 (50.0) 2 (4.4)
Cdx2 EXPRESSION AND MISMATCH REPAIR STATUS
There was a major significant association between reduced
Cdx2 expression and MMR-deficiency. The AUC value for Cdx2
expression in tumor was 0.87 indicating 87% accuracy for dis-
criminating MMR-proficient and – deficient cancers (Figure 2B).
The OR (95% CI) was 0.96 (0.95–0.98); p< 0.0001. The ROC
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curve was used as a basis for the identification of an optimal
threshold value for considering tumors with “focal” and “diffuse”
expression and determined to be 90%. Of the 115 patients with
diffuse expression of Cdx2, 114 were MMR-proficient (99.1%
specificity) and of the 27 MMR-deficient patients 26 had only
focal expression (96.3% negative predictive value). There were
174 patients with MMR-proficient cancers, of which 60 (34.5%)
indeed showed loss of Cdx2. Cdx2 loss among patients with MMR-
proficient cancers was significantly and unfavorably related to
survival (p= 0.0102; Figure 2C). Again, in multivariable analy-
sis, Cdx2 loss was associated with worse outcome after adjusting
for pT and pN [p= 0.0414; HR (95% CI): 0.54 (0.3–0.98)], but
not when clinical metastasis stage was added.
The AUC for Cdx2 expression in lymph nodes and MMR sta-
tus was 0.943 indicating 94% discriminatory ability of the protein.
The OR (95% CI) was 0.93 (0.87–0.99); p= 0.037. Using the ROC
curve for the selection of a threshold value, tumors with <30%
staining were considered “focal” and >30% considered “diffuse”
for Cdx2 expression. Of the 45 cases with diffusely expressing
Cdx2, 43 were MMR-proficient (95.6% specificity), whereas 7/9
MMR-deficient cancers showed focal expression of Cdx2 (77.8%
NPV).
DISCUSSION
The findings of this study suggest that reduced expression of Cdx2
in primary tumors and lymph node metastases is an accurate
predictor of MMR-deficiency in colorectal cancer. Moreover, loss
of Cdx2 is a poor prognostic factor, even among patients with
MMR-proficient cancers.
In a first step, we examined the specificity of Cdx2 for MMR sta-
tus. The ROC curve for this analysis underlines the major discrim-
inatory power of reduced Cdx2 expression for MMR-deficiency in
both colorectal cancers and lymph nodes. Previous reports by our
group and others have highlighted similar findings. Using a tissue
microarray containing more than 600 patient tissues,Baba and col-
leagues showed a high specificity of reduced Cdx2 expression for
MSI-high colorectal cancers (22). The protein expression of Cdx2
in MMR-proficient versus deficient cancers has been reported at
84 versus 61% on average, again using tissue microarrays (14). Our
study goes one step further and uses whole tissue sections for the
establishment of both MMR status and Cdx2 expression. Indeed,
all MMR-deficient cancers with the exception of one case showed
only focal positivity for Cdx2 expression.
Despite this observation, a subgroup of MMR-proficient can-
cers also shows focal positivity for Cdx2. Our hypothesis is that
Cdx2 loss may be an important marker of other molecular changes
associated with the serrated pathway to colorectal cancer, including
BRAF mutation and high-level CIMP. Indeed, we could previ-
ously show using a cohort of more than 300 patients, that loss of
Cdx2 was nearly 100% specific for BRAF mutation, and found in
23/24 mutated cases (23). Baba and colleagues as well as Walsh
et al. found loss of Cdx2 in BRAF mutated tumors and a signif-
icantly more frequent number of cases in tumors with CIMP-H
(22, 24). Loss of Cdx2 has also been found to be an indepen-
dent predictor of the CIMP-H phenotype (25). Figure 3 illustrates
some of the changes hypothesized to occur during the serrated
pathway. We believe that loss of Cdx2 expression occurs prior
FIGURE 3 | Schematic diagram illustrating a proposal for the
involvement of Cdx2 during progression of cancers through the
serrated pathway.
to the establishment of MSI and only after the development of
both BRAF mutation and CIMP. Although the evidence fits well
for an involvement of Cdx2 in the serrated pathway, whether this
molecule is actually functionally involved as a cause rather than
a consequence of progression of tumors within this pathway has
not yet been established.
Next, we evaluated the association between focal expression of
Cdx2 and clinicopathological features. Our results point toward
an association of Cdx2 with an array of important and adverse
prognostic features including unfavorable overall survival. Our
findings are in line with previous work from our group using a sin-
gle punch tissue microarray showing strong correlations between
Cdx2 loss and pT, pN, tumor grade, and vascular invasion on more
than 1000 tumors. Baba and colleagues showed similar results of
Cdx2 loss with more advanced TNM stage, higher tumor grade,
mucinous, or signet ring cell histology (22). These results are in
agreement with Choi et al. who show loss of Cdx2 expression asso-
ciated with advanced Dukes’ stage and more poorly differentiated
cancers (26). Unfavorable survival times are reported by several
groups upon reduced Cdx2 expression (22, 27). In addition, the
predilection for female gender and more right-sided tumor loca-
tion has also been observed in other studies (22, 28). We also show
that the unfavorable impact of Cdx2 is maintained in patients with
MMR-deficient cancers.
Thirdly, we evaluated for the first time Cdx2 expression in
matched lymph node metastases. We found no differences in
expression between lymph nodes and primary colorectal cancers.
These results appear to indicate that a further “evolution” leading
to loss of Cdx2 after lymph node spread is unlikely.
To conclude, Cdx2 is significantly reduced in patients with
MMR-deficient colorectal cancers, but is not limited to these
tumors. It is an unfavorable prognostic factor, even among
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patients with MMR-proficient cancers. Taken together with pre-
vious reports on BRAF and CIMP, we hypothesize that Cdx2 loss
may play an early role in the progression of cancers arising through
the serrated pathway.
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